The consequences of attention-deficit/hyperactivity disorder in adults

Journal of Psychiatric Practice

Volumn 13, Issue 5, 2007, Pages 318-327

  Goodman, David W ^a  

^a Johns Hopkins Green Spring   (United States)

Author keywords

Adult ADHD; Attention deficit hyperactivity disorder (ADHD); Dopamine; Quality of life; Substance use disorder

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; DESIPRAMINE; METHYLPHENIDATE; PLACEBO;

AGITATION; ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CIGARETTE SMOKING; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; CONSTIPATION; COST OF ILLNESS; DECREASED APPETITE; DIAGNOSTIC ACCURACY; DISEASE COURSE; DIZZINESS; DRIVING ABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ECONOMIC ASPECT; FAMILY INTERACTION; HEADACHE; HUMAN; HUMAN RELATION; INSOMNIA; NAUSEA; NERVOUSNESS; PERSONAL VALUE; QUALITY OF LIFE; REVIEW; SCHOOL; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL ASPECT; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SUBSTANCE ABUSE; URINE RETENTION; WEIGHT REDUCTION; WORK; XEROSTOMIA;

ACHIEVEMENT; ADULT; AGE FACTORS; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HUMANS; IMPULSIVE BEHAVIOR; MALE; MENTAL DISORDERS; METHYLPHENIDATE; PROPYLAMINES; QUALITY OF LIFE; SEX DISTRIBUTION; SOCIAL ADJUSTMENT; SUBSTANCE-RELATED DISORDERS;

EID: 34748862354     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000290670.87236.18     Document Type: Review

References (74)

1. Biederman J, Faraone S. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-48.
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23.
3. Biederman J. Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 2005;57:1215-20.
4. Waldman ID, Gizer IR. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev 2006;26:396-432.
5. Biederman J, Faraone S, Monuteaux M. Impact of exposure to parental attention-deficit hyperactivity disorder on clinical features and dysfunction in the offspring. Psychol Med 2002;32:817-27.
6. Palacio JD, Castellanos FX, Pineda DA, et al. Attention-deficit/ hyperactivity disorder and comorbidities in 18 Paisa Colombian multigenerational families. J Am Acad Child Adolesc Psychiatry 2004;43:1506-15.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000.
8. Riccio C, Wolfe M, Davis B, et al. Attention deficit hyperactivity disorder: Manifestation in adulthood. Arch Clin Neuropsychol 2005;20:249-69.
9. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry 2004;161:1948-56.
10. Clarke S, Heussler H, Kohn M. Attention deficit disorder: Not just for children. Int Med J 2005;35:721-5.
11. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:187-201.
12. Wasserstein J. Diagnostic issues for adolescents and adults with ADHD. J Clin Psychiatry 2005;61:535-47.
13. Weiss M, Weiss J. A guide to the treatment of adults with ADHD. J Clin Psychiatry 2004;65(suppl 3):27-37.
14. Wilens T, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J Clin Psychiatry 2004;65:1301-13.
15. Biederman J, Mick E, Faraone S. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. Am J Psychiatry 2000;157:816-8.
16. Faraone S, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychol Med 2005;35:1-7.
17. Secnik K, Swensen A, Lage M. Comorbidities and costs of adult patients diagnosed with attention-deficit/hyperactivity disorder. Pharmacoeconomics 2005;23:93-102.
18. Young S, Toone B, Tyson C. Comorbidity and psychosocial profile of adults with attention deficit hyperactivity disorder. Pers Individ Dif 2003;35:743-55.
19. Biederman J, Faraone S, Monuteaux M, et al. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol Psychiatry 2004;55:692-700.
20. Volkow ND, Fowler JS, Wang G-J, et al. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: Results from imaging studies. European Neuropsychopharmacology 2002;12:557-66.
21. Volkow ND, Wang G-J, Fowler JS, et al. Effects of methylphenidate on regional brain glucose metabolism in humans: Relationship to dopamine D2 receptors. Am J Psychiatry 1997;154:50-5.
22. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: A review and suggested future directions. Biol Psychiatry 2005;57:1273-84.
23. Hale TS, Bookheimer S, McGough JJ, et al. Atypical brain activation during simple and complex levels of processing in adult ADHD: An fMRI study. J Atten Disord 2007 May 9; [Epub ahead of print].
24. Nadeau K. Career choices and workplace challenges for individuals with ADHD. J Clin Psychiatry 2005;61:549-63.
25. Biederman J, Faraone S, Spencer T, et al. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry 2006;67:524-40.
26. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990;29:546-57.
27. Rosler M, Retz W, Retz-Junginger P, et al. Prevalence of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 2004;254:365-71.
28. Babinski L, Hartsough C, Lambert N. Childhood conduct problems, hyperactivity-impulsivity, and inattention as predictors of adult criminal activity. J Child Psychol Psychiatry 1999;40:347-55.
29. Eyestone L, Howell R. An epidemiological study of attention-deficit hyperactivity disorder and major depression in a male prison population. Bull Am Acad Psychiatry Law 1994;2:181-93.
30. Barkley R. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:233-60.
31. Barkley R, Murphy K, Dupaul G, et al. Driving in young adults with attention deficit hyperactivity disorder: Knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc 2002;8:655-72.
32. Fried R, Petty C, Surman C, et al. Characterizing impaired driving in adults with attention-deficit/hyperactivity disorder: A controlled study. J Clin Psychiatry 2006;67:567-74.
33. Knouse L, Bagwell C, Barkley R, et al. Accuracy of self-evaluation in adults with ADHD. Evidence from a driving study. J Atten Disord 2005;8:221-34.
34. Cox D, Humphrey J, Merkel R, et al. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract 2004;17:235-9.
35. Barkley RA, Cox D. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res 2007;38:113-28.
36. Kay GG, Pakull B, Clark TM, et al. The effect of Adderall XR® treatment on driving performance in young adults with ADHD. Poster presented at the 17th Annual US Psychiatric & Mental Health Congress, San Diego, CA, November 19, 2004.
37. Wilens T. Attention-deficit/hyperactivity disorder and the substance use disorders: The nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 2004;27:283-301.
38. Schubiner H. Substance abuse in patients with attention-deficit hyperactivity disorder: Therapeutic implications. CNS Drugs 2005;19:643-55.
39. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 2005;62:1142-47.
40. Biederman J, Monteaux MC, Mick E, et al. Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity disorder. Biol Psychiatry 2006;59:258-64.
41. Levin F, Evans S, Kleber H. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend 1998;52:15-25.
42. Wilens T, Faraone S, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-85.
43. Wilens T, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45:408-14.
44. Swensen A, Birnbaum H, Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health 2004;35:346.e1-e9.
45. Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005;3:5.
46. Biederman J, Faraone SV. The effects of attention-deficit/ hyperactivity disorder on employment and household income. MedGenMed 2006;8:12.
47. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1147-53.
48. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. Biol Psychiatry 2005;57:793-801.
49. Spencer TJ, Adler LA, McGough JJ, et al, for the Adult ADHD Research Group. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007;61:1380-7.
50. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, norms, and clinical interpretation. New York: Guilford; 1998.
51. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales, Technical Manual. North Tonawanda, NY: Multi-Health Systems; 1999.
52. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ. No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976:218-22.
53. Adler LA, McGough J, Muniz R, et al Long-term efficacy of extended release dexmethylphenidate in adult ADHD. Poster presented at the 158th Annual Meeting of the American Psychiatric Association; May 23, 2005; Atlanta, Georgia.
54. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: A randomized, controlled trial. CNS Spectr. 2006;11:625-39.
55. Biederman J. Mixed amphetamine salts XR in adults with ADHD: 18-month interim analysis. Presented at the 157th Annual Meeting of the American Psychiatric Association; May 6, 2004; New York, NY.
56. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-20.
57. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901.
58. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/ hyperactivity disorder: an interim analysis. J Clin Psychiatry 2005;66:294-99.
59. Goodman D. Treatment and assessment of ADHD in adults. In: Biederman J, ed. ADHD across the life span: From research to clinical practice - an evidence-based understanding. Hasbrouck Heights, NJ: Veritas Institute for Medical Education, Inc and MedLearning, Inc.; 2006:227-70.
60. Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005;43:831-42.
61. Rostain AL, Ramsay JR. A combined treatment approach for adults with ADHD: Results of an open study of 43 patients. J Atten Disord 2006;10:150-9.
62. Brown TE. Brown Attention-Deficit Disorder Scales. San Antonio, TX: The Psychological Corporation; 1996.
63. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50:565-76.
64. Mannuzza S, Klein RG, Bessler A, et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997;36:1222-7.
65. Mannuzza S, Klein RG, Bessler A, et al. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998;155:493-8.
66. Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002;111:279-89.
67. Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: Antisocial activities and drug use. J Child Psychol Psychiatry 2004;45:195-211.
68. Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med 2007;37:97-107.
69. Lamberg L. ADHD often undiagnosed in adults: Appropriate treatment may benefit work, family, social life. JAMA 2003;290:1565-7.
70. Okie S. ADHD in adults. N Engl J Med 2006;354:2637-41.
71. Adler LA, Sutton VK, Moore RJ, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 2006;26:648-52.
72. Goodman DW, Ginsberg L, Weisler RH, et al. An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005;10(suppl 20):26-34.
73. Landgraf JM, Shingler T. ADHD-specific quality of life with mixed amphetamine salts extended release in adults with ADHD. Poster presented at American Psychiatric Association 159th Annual Meeting; May 24, 2006; Toronto, Canada.
74. Landgraf JM. Monitoring quality of life in adults with ADHD: Reliability and validity of a new measure. J Atten Disord 2007 May 9; [Epub ahead of print].